Tell us which antibody you’d like to have next

Thank you for taking time to help us develop the antibodies that meet your needs.

Please tick the antibody drugs you are interested in, and let us know if you would like to be informed when the anti-drug antibodies are released.

Etanercept                       Enbrel®
Abciximab                        ReoPro®
Denosumab                     Prolia®, Xgeva®
Ofatumumab                   Arzerra®, HuMax-CD20
Eculizumab                      Soliris®
Certolizumab pegol       Cimzia®
Ranibizumab                   Lucentis®
Abatacept                       Orencia®
Ipilimumab                       Yervoy®
Nivolumab                       Opdivo®
Pembrolizumab               Keytruda®
Pertuzumab                     Perjeta®
Vedolizumab                   Entyvio®
Notify me when new antibodies are available.
Do you know we can develop the anti-idiotypic antibodies specific to your biotherapeutics? Please find out more about our Custom Anti-Drug Antibodies


ACTEMRA® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.Tysabri® is a registered trademark of Elan Pharmaceuticals, Inc. Enbrel® is a registered trademark of Amgen Inc. Vectibix® is a registered trademark of Amgen. Synagis® is a registered trademark of MedImmune, LLC. REOPRO® is a trademark of Eli Lilly and Company. Prolia® is a trademark of Amgen Inc. ARZERRA® is a registered trademark of the GlaxoSmithKline group of companies. Soliris® is a trademark of Alexion Pharmaceuticals. CIMZIA® is a trademark of the UCB Group of Companies. Lucentis is a registered trademark of Genentech Inc.